Bristol-Myers Squibb
BMY
BMY
1,744 hedge funds and large institutions have $75B invested in Bristol-Myers Squibb in 2018 Q1 according to their latest regulatory filings, with 128 funds opening new positions, 593 increasing their positions, 777 reducing their positions, and 96 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
1,744
Holders Change
+11
Holders Change %
+0.63%
% of All Funds
40.03%
Holding in Top 10
59
Holding in Top 10 Change
+14
Holding in Top 10 Change %
+31.11%
% of All Funds
1.35%
New
128
Increased
593
Reduced
777
Closed
96
Calls
$2.17B
Puts
$1.11B
Net Calls
+$1.07B
Net Calls Change
+$858M
Top Buyers
| 1 |
Primecap Management
Pasadena,
California
|
+$624M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$198M |
| 3 |
D.E. Shaw & Co
New York
|
+$197M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$194M |
| 5 |
Goldman Sachs
New York
|
+$191M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$407M |
| 2 |
State Street
Boston,
Massachusetts
|
-$198M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$127M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$125M |
| 5 |
JPMorgan Chase & Co
New York
|
-$124M |
